The Bloodpressure Program™ It is highly recommended for all those who are suffering from high blood pressure. Most importantly, it doesn’t just treat the symptoms but also addresses the whole issue. You can surely buy it if you are suffering from high blood pressure. It is an easy and simple way to treat abnormal blood pressure.
How do baroreflex activation devices influence BP, what implant trials reveal, and how does this compare with renal denervation?
Baroreflex activation therapy (BAT) devices lower blood pressure by electrically stimulating the body’s natural pressure sensors, effectively “tricking” the brain into thinking blood pressure is too high and initiating a system-wide calming response. Pivotal implant trials, such as those for the Barostim™ system, have revealed that these devices can produce a significant and durable reduction in blood pressure in patients with resistant hypertension. When compared with renal denervation (RDN), another device-based therapy, baroreflex activation therapy appears to offer a more potent and consistent blood pressure-lowering effect, although it involves a more invasive implant procedure. Both therapies represent a major step forward for patients who have exhausted pharmacological options.
How Baroreflex Activation Devices Influence Blood Pressure 🧠❤️
To understand how these devices work, it’s essential to first understand the body’s natural baroreflex system. Located in the carotid arteries (in the neck) and the aorta are specialized nerve endings called baroreceptors. These are the body’s primary pressure sensors, constantly monitoring the stretch and strain on the arterial walls with every heartbeat.
- Sensing High BP: When blood pressure rises, the artery walls stretch, which activates the baroreceptors.
- Signaling the Brain: The baroreceptors send a rapid volley of signals up to the brainstem.
- The Brain’s Response: The brain interprets these signals as a sign of high blood pressure and immediately orchestrates a calming response via the autonomic nervous system. This includes:
- Decreasing sympathetic outflow: This is the “fight-or-flight” part of the nervous system. Reducing its activity causes blood vessels to relax and widen (vasodilation) and the heart to beat less forcefully.
- Increasing parasympathetic (vagal) outflow: This is the “rest-and-digest” system. Increasing its activity slows the heart rate.
- Signaling the Kidneys: The brain tells the kidneys to excrete more sodium and water, which reduces blood volume.
The net result of this reflex is a swift and effective reduction in blood pressure. In many people with hypertension, this natural reflex is impaired or “reset” to a higher baseline, meaning it doesn’t kick in until blood pressure is dangerously high.
Baroreflex activation therapy (BAT) hijacks this natural pathway. The system consists of two main components:
- An implantable pulse generator (IPG), similar in size to a small pacemaker, which is placed under the skin in the upper chest.
- A thin lead with an electrode that is surgically placed on the outside of the carotid artery in the neck, right over the location of the carotid baroreceptors.
The device works by sending continuous, low-level electrical impulses to the electrode. This electrical energy artificially stimulates the baroreceptors, fooling them into thinking the artery wall is stretching due to high blood pressure. This sends a constant stream of “high pressure” signals to the brain, triggering the body’s natural calming reflex 24 hours a day. The brain responds just as it would to true high blood pressure, leading to a sustained reduction in sympathetic tone, vasodilation, and a decrease in heart rate, which collectively lower the patient’s blood pressure.
What the Implant Trials Reveal 🔬
The journey of BAT has been marked by several key clinical trials that have established its safety and efficacy.
- Rheos Pivotal Trial (First-Generation Device): This was the initial large-scale, randomized trial for the first-generation Rheos system. While it did show a significant blood pressure reduction, the device was large, and the procedure was complex, involving two electrodes. The trial established the proof of concept but highlighted the need for a more refined system.
- Barostim neo™ Trials (Second-Generation Device): The development of the Barostim neo system was a major advance. This device is significantly smaller (about the size of a matchbox) and uses a single, smaller carotid electrode, making the implant procedure much simpler and safer.
- The Barostim neo Pivotal Trial was a randomized, controlled trial that enrolled patients with resistant hypertension and heart failure. The results for the hypertension cohort were highly positive. At 6 months, 54% of patients in the BAT group achieved a systolic blood pressure below 140 mmHg, compared to only 26% in the control group.
- The long-term follow-up data is particularly compelling. Studies have shown that the blood pressure reduction is durable, with significant reductions maintained out to 5 and 6 years. The average office systolic blood pressure reduction in long-term studies is often in the range of 25-35 mmHg, a very substantial and clinically meaningful effect.
- Beyond blood pressure, trials have also shown that BAT leads to improvements in cardiac structure (regression of left ventricular hypertrophy) and function, as well as a reduction in the risk of new-onset atrial fibrillation.
These trials have successfully demonstrated that Baroreflex Activation Therapy is a safe and effective long-term treatment for patients with resistant hypertension who have failed to respond to medications.
Comparison with Renal Denervation (RDN)
Renal denervation is another device-based therapy for resistant hypertension. It works by using a catheter to deliver radiofrequency or ultrasound energy to disrupt the sympathetic nerves surrounding the renal arteries. Like BAT, it aims to reduce overall sympathetic tone.
The most significant differentiator is the magnitude of the blood pressure-lowering effect. The published data to date suggest that Baroreflex Activation Therapy provides a more powerful and reliable reduction in blood pressure compared to renal denervation. This is likely because BAT influences the central command center of the sympathetic nervous system in the brain, leading to a more global effect, whereas RDN targets a more peripheral part of the system.
However, this greater efficacy comes at the cost of a more invasive procedure. The decision between BAT and RDN is therefore a clinical judgment based on the severity of the hypertension, the patient’s overall health and comorbidities (like heart failure), and patient preference regarding the type of procedure.
In conclusion, baroreflex activation therapy represents a highly effective, evidence-based option for a select group of patients with the most difficult-to-treat hypertension. By tapping into the body’s own powerful blood pressure control system, it offers a durable, “always-on” therapy that can significantly improve cardiovascular health. While renal denervation provides a less invasive alternative, BAT currently holds the advantage in terms of the sheer power of its blood pressure-lowering effect, making it a crucial tool for managing the highest-risk patients.
Frequently Asked Questions (FAQ) 🤔
1. Is the Barostim device visible after it’s implanted? The pulse generator is implanted under the skin in the upper chest, similar to a pacemaker. In very thin individuals, a small bulge may be visible, but for most people, it is not noticeable under clothing. The incision in the neck is usually small and heals to a fine line.
2. Can I feel the stimulation from the device? When the device is first activated and programmed by your doctor, you might feel a slight tingling or pulling sensation in your neck. This is normal, and the device is carefully programmed to a level that provides a therapeutic effect without causing any discomfort. Most patients are not aware of the stimulation in their daily life.
3. Will I need to have the Barostim device replaced? The pulse generator is powered by a battery, much like a pacemaker. The battery life depends on the stimulation settings but typically lasts for several years. When the battery is nearing the end of its life, the pulse generator can be replaced in a simple outpatient procedure. The lead in the neck is designed to be a permanent implant and does not usually need to be replaced.
4. Can I have an MRI with a Barostim device? The Barostim neo™ system is conditionally MRI-safe. This means that under specific conditions and with the right protocols, patients can safely undergo an MRI scan. You must always inform the MRI staff that you have an implanted device.
5. Who is the ideal candidate for Baroreflex Activation Therapy? The ideal candidate is a patient who has been diagnosed with resistant hypertension, meaning their blood pressure remains high despite taking three or more medications at optimal doses, including a diuretic. It is also a very effective therapy for patients who have both high blood pressure and heart failure with a reduced ejection fraction. The decision is made after a thorough evaluation by a team of hypertension and heart failure specialists.
I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. Learn more |